Related Experiment Video

Updated: Jul 11, 2025

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19
08:48

Dynamic Monitoring of Seroconversion using a Multianalyte Immunobead Assay for Covid-19

Published on: February 16, 2022

2.9K

Thrombotic Markers in Pregnant Patients with and without SARS-CoV-2 Infection

Ann M Bruno1,2, Amanda A Allshouse1, Ashley E Benson3

  • 1Department of Obstetrics & Gynecology, University of Utah Health, Salt Lake City, Utah.

American Journal of Perinatology
|November 15, 2023
PubMed

Insights

COVID-19 in pregnant individuals did not alter D-dimer levels or increase thrombosis risk. However, higher than expected rates of lupus anticoagulant (LAC) positivity were observed in SARS-CoV-2 infected pregnancies.

Area of Science:

  • Obstetrics and Gynecology
  • Infectious Diseases
  • Hematology

Background:

  • Coronavirus disease 2019 (COVID-19) is linked to coagulation issues and a higher risk of blood clots.
  • Pregnant individuals with Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may face unique thrombotic risks.

Purpose of the Study:

  • To investigate D-dimer levels and lupus anticoagulant (LAC) positivity in pregnant individuals with and without SARS-CoV-2 infection.
  • To compare thrombotic markers between infected and non-infected pregnant individuals, considering disease severity.

Main Methods:

  • A prospective cohort study included pregnant individuals delivering between April 2020 and March 2022.
  • SARS-CoV-2 positive individuals were compared to a control group; D-dimer and LAC positivity were assessed at delivery.
  • Thromboembolic events and disease severity were secondary outcomes.

Main Results:

  • No significant difference in D-dimer levels was found between SARS-CoV-2 positive and negative pregnant individuals.
  • A higher rate of LAC positivity was observed in the SARS-CoV-2 positive group (4%) compared to the negative group (0%), though not statistically significant.
  • No clinically apparent thromboses occurred in either group, and D-dimer or LAC positivity did not correlate with COVID-19 severity.

Conclusions:

  • SARS-CoV-2 infection in pregnancy did not significantly alter D-dimer levels or increase the incidence of thromboembolic events.
  • Elevated rates of LAC positivity were noted in pregnant individuals with SARS-CoV-2 infection, warranting further investigation.
  • Despite altered coagulation markers, clinically significant thrombosis was not observed in this cohort.
Abstract

More Related Videos

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles05:31

Author Spotlight: Modeling an Aspect of Preeclampsia in Female Mice Using Hypoxic Human Placenta-Derived Small Extracellular Vesicles

Published on: January 26, 2024

849
Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection10:25

Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection

Published on: June 5, 2021

4.7K

Related Concept Videos

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
12
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
97
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
37